Abstract We previously determined sequenced the PNLIP gene encoding pancreatic lipase in cell lines of subjects with clinical deficiency of pancreatic lipase (MIM 246600) and found no putative disease-causing mutations. As part of the ongoing analysis of the genomic DNA of these subjects, we now report the development of genomic amplification primers to sequence the coding regions of CLPS, CEL, PLRP1, and PLRP2, encoding pancreatic co-lipase, carboxyl-ester lipase, and pancreatic-lipase-related proteins-1 and -2, respectively. Whereas we found no putative diseasecausing missense or nonsense mutations in these samples, we discovered a total of 13 common polymorphisms (12 single nucleotide polymorphisms) in these four genes. Genotypes of these polymorphisms may be useful in future association analyses.
Introduction
Pancreatic lipase deficiency (PLD; MIM 246600) is characterized by malabsorption of long chain triglyceride fatty acids, failure to thrive in infancy and childhood, and the absence of pancreatic lipase (PL) secretion after secretin stimulation (Sheldon 1964; Rey et al. 1966) . We have previously shown that the PNLIP gene encoding PL is not mutated in PLD (Hegele et al. 2001) . Other candidate genes for PLD include those with related function, such as CLPS and CEL, which encode pancreatic co-lipase (Sims and Lowe 1992) and carboxyl-ester lipase (Lidberg et al. 1992) , respectively, and with related structures, such as PLRP1 and PLRP2, which encode PL-related proteins-1 and -2, respectively (Giller et al. 1992 ). We sequenced these four candidate genes in subjects with PLD. Whereas no putative disease-causing mutations were discovered, we found several common polymorphisms that we further characterized in normal subjects.
Materials and methods

Study subjects
Cell lines of PL-deficient probands
Lymphoblasts from four PLD patients were purchased from Coriell Cell Repositories (Camden, N.J.). These subjects have been previously reported (Hegele et al. 2001) . Briefly, subject GM13278 was a 3-year-old Caucasian female with chronic diarrhea, failure to thrive, and complete deficiency of PL activity following secretin stimulation. Subject GM13322 was a 2-year-old Hispanic male with failure to thrive, developmental abnormalities, and complete deficiency of PL activity following secretin stimulation. Subject GM13343 was a 5-year-old Caucasian male with chronic diarrhea, failure to thrive, and complete deficiency of PL activity following secretin stimulation. Subject GM13344 was a 2-year-old Caucasian male with failure to thrive, developmental abnormalities, and complete deficiency of PL activity following secretin stimulation. No family data were available for any subject.
Normal controls
Samples from a DNA archive of 50 normal Caucasian subjects were used to determine polymorphism allele frequencies. Five of these normal control DNA samples were included in the screening experiments. Samples were available from 50 Chinese and 50 African subjects for additional genotyping of polymorphisms. turer's instructions (Puregene, Gentra Systems, Minneapolis, Minn.). Genomic DNA from neonatal samples was prepared as described (Hegele et al. 2001 ).
Screening candidate genes for DNA variants
In order to amplify CLPS, CEL, PLRP1, and PLRP2 coding regions and intron-exon boundaries from genomic DNA, primer sets were developed by using NCBI sequences. Gene names, OMIM numbers, National Center for Biotechnology Information (NCBI) numbers, primer sequences, and product sizes are shown in Table 1 . Primers were each designed to anneal at 60°C, which allowed for the use of a single amplification apparatus for all reactions. Amplification conditions were: 94°C for 5 min, followed by 30 cycles comprising 30 s each at 94°C, 60°C, and 72°C, ending with a single 10-min extension step at 72°C. All samples were directly sequenced in a Prism 377 Automated DNA sequencer (PE Applied Biosystems, Mississauga, Canada). 
Results
Identification of candidate gene polymorphisms
Genomic DNA from the cell lines from the four PLD subjects and from five normal Caucasian controls were screened by using the amplification primers from Table 1 and the amplification program described above. The polymorphisms detected in the screening experiments are shown in Table 2 . Frequencies of the minor allele of each polymorphism in 50 Caucasians are shown in Table 2 , in addition to frequencies of specific alleles in 50 Chinese and 50 African subjects. None of the observed genotype frequencies deviated from the expectations according to the Hardy-Weinberg equation.
Discussion
We report: (1) primer sets that amplify the entire sequence of CLPS, CEL, PLRP1, and PLRP2, encoding pancreatic co-lipase, carboxyl-ester lipase, and pancreatic-lipase-related proteins-1 and -2, respectively; (2) no mutations in these four genes in subjects with PLD; (3) a total of 13 common polymorphisms, 12 being single nucleotide polymorphisms (SNPs), in these four genes.
Of the 12 SNPs, 11 appear not to have been previously reported, whereas only PLRP1 L461P has been cited in the NCBI SNP database (no. rs1049125). The PLRP1 IVS8 +20C fi T SNP was first identified in subject GM13322 and appears to be specific for subjects of African origin, suggesting that subject GM13322 might have had African admixture. The PLRP2 W357X SNP is also of particular interest since it is a common nonsense polymorphism that predicts premature truncation, by $24%, of the gene product, whose full length form is expressed and has lipase activity (Giller et al. 1992) . However, in the absence of evidence of expression, functional data, or additional clinical correlation, the relevance of such a truncated gene product is uncertain. The common SNPs in these genes may prove to be helpful in future association and/or pharmacogenetic studies.
